MOLECULAR SERVICES

LEFT: Medical Director of Molecular Oncology/Genetics Laboratory, **Noah Brown, M.D.,** joined the faculty of the University of Michigan in 2014. His areas of interest include novel molecular alterations in head and neck and hematolymphoid neoplasms; optimal techniques for the detection of clinically actionable molecular alterations.

RIGHT: Technical Director of Molecular Oncology/Genetics Laboratory, **Bryan Betz, Ph.D.,** joined the faculty of the University of Michigan in 2007. His areas of interest include application of emerging technologies to clinical molecular diagnostics; cancer molecular genetics.



LABORATORIES

mlabs.umich.edu 800.862.7284

<complex-block>

Michigan Medicine Laboratories (MLabs) is a CLIA-certified/CAP accredited laboratory offering state of the art molecular testing services that support diagnosis, prognosis and therapeutic guidance for your patients.

Our highly experienced faculty, ABMGG board-certified geneticist, medical technologist and bioinformaticians are dedicated to delivering the highest quality laboratory results to meet the needs of today's patients in a cost effective and personalized manner.

142k SQUARE FOOT BRAND NEW STATE OF THE ART FACILITY

30⁺ YEARS OF EXPERIENCE

26 MOLECULAR, PEDIATRIC & GENETIC COUNSELORS AND CONSULTANTS

MOLECULAR ONCOLOGY & GENETICS

CONSULTANTS



Aleodor Andea M.D.



David O. Ferguson M.D., Ph.D.



Lakshmi P. Kunju M.D.



Aaron Udager M.D., Ph.D.



Bryan Betz Ph.D.



Thomas Giordano M.D., Ph.D.



David B. Lombard M.D., Ph.D.



Thomas E. Wilson M.D., Ph.D.



Noah Brown M.D.



Paul Harms M.D., Ph.D.



Rohit Mehra M.D.



Arul M. Chinnaiyan M.D., Ph.D.



Jeffrey Innis M.D., Ph.D.



Marwan Tayeh Ph.D.



SERVICES

MOLECULAR ONCOLOGY/GENETICS

Performing over 20,000 assays annually with an average turn-around-time of 10 days, our Molecular Oncology and Genetics Laboratory specializes in offering cuttingedge molecular tests to aid in cancer diagnosis, selection of therapy, determination of prognosis, and monitoring of residual disease. An expanding menu of tests are offered in disease-specific service lines to provide a comprehensive testing solution for each disease, including colorectal cancer, non-small cell lung cancer, melanoma, gastrointestinal stromal tumor, glioma, sarcoma, myeloproliferative neoplasms, acute myeloid leukemia, lymphoproliferative disorders, and others. The implementation of next generation sequencing technology to many tests and panels now provides the ability to detect mutations with excellent sensitivity and broad coverage while also preserving the ability to test small biopsies and challenging specimens with low neoplastic cell content. 3% ONS RATE

64 MOLECULAR ONCOLOGY TESTS

MOLECULAR GENETICS

MLab's Molecular Genetics Laboratory has two ABMGG board certified Geneticists, Marwan Tayeh, PhD; Jeffrey Innis, MD, PhD and a board certified Genetic Counselor. Molecular Genetics Laboratory offers comprehensive clinical testing for germline genetic diseases and is committed to assisting clinicians in identifying genetic aberrations to facilitate clinical diagnosis, management, and genetic counseling. Molecular Genetics offers a variety of NGS germline cancer panels including: Breast and Ovarian, Colorectal, Pancreatic, Renal, Endometrial/Uterine, Melanoma, Stomach, Prostate, and Paraganglioma. In addition, the laboratory offers Sanger sequencing for a long list of genes, SNP Chromosomal Microarray, mutation screening for cystic fibrosis, Methylation-Specific PCR for Prader-Willi/Angelman syndrome and Fragile X, MLPA for deletion/duplication detection of BRCA1, BRCA2, TP53, PTEN, MECP2, CFTR, and SMN1 exons 7 and 8 deletions.

TRANSLATIONAL PATHOLOGY

MLabs comprehensively characterize disease using novel bioinformatics approaches and high-throughput technologies. This work facilitates more accurate, early detection methods, assists in the prediction of prognosis, defines disease subtypes, as well as assists in the assessment of treatment efficacy. These efforts could result in the future development of targeted therapies.

Our featured tests include PCA3 (Gen-Probe) test for prostate cancer detection and MyProstateScore (MPS) an early detection test for prostate cancer that combines the amount of serum PSA, with the amounts of two genes in the urine. These two genes, TMPRSS2:ERG and PCA3, are specific for prostate cancer, meaning they are rarely present at high levels in the urine of men without prostate cancer.

PANELS

75 genetic tests

SELECT TEST MENU

Molecular Oncology

ACUTE MYELOID LEUKEMIA NPM1 Mutation (PCR) FLT3 Mutation (PCR) CEPBA Mutation (Sanger) IDH1 and IDH2 Mutation (Sanger) KIT D816V Mutation (PCR) KIT Mutation for AML - Exons 8, 17 (Sanger) PML/RARA t(15;17) Translocation Qualitative (PCR)

MYELOPROLIFERATIVE NEOPLASMS

JAK2 V617F Mutation (PCR) JAK2 Exon 12 Mutation (PCR) CALR Mutation (PCR) MPL Mutation (PCR) KIT D816V Mutation (PCR) BCR/ABL1 Analysis, Quantitative (PCR) BCR/ABL1 Kinase Domain Mutation (Sanger)

LYMPHOPROLIFERATIVE DISORDERS

B Cell Clonality (PCR) (IGK & IGH Gene Rearrangement) B Cell Clonality (PCR) (IGK Gene Rearrangement) B Cell Clonality (PCR) (IGH Gene Rearrangement) T Cell Clonality (PCR) (TRG & TRB Gene Rearrangement) T Cell Clonality (PCR) (TRG Gene Rearrangement) T Cell Clonality (PCR) (TRB Gene Rearrangement) IGH/BCL2 t(14;18) Translocation (PCR) IGH/BCL2 t(14;18) Translocation (FISH) BCL6 (3q27) Rearrangement (FISH) MYC (8q24) Rearrangement (FISH) MALT1 (18q21) Rearrangement (FISH) MYD88 (L265P) Mutation (PCR) BRAF V600E/V600K Mutations (PCR)

COLORECTAL AND ENDOMETRIAL CANCER

Colorectal Cancer (NGS) Panel*

Germline MLH1 Promoter Methylation (PCR) KRAS Mutation (NGS) MLH1 Promoter Methylation (PCR) NRAS Mutation (NGS) BRAF V600E/V600K Mutations (PCR) Microsatellite Instability Analysis (PCR) UGT1A1 Promoter Genotyping (PCR) Circulating Tumor Cells (CellSearch)

GASTROINTESTINAL STROMAL TUMOR

KIT Mutation - Exons 9,11,13,17 (Sanger) PDGFRA Mutation for GIST (Sanger)

GENITOURINARY TUMOR

FGFR Mutation/Translocation (NGS) BRAF (7q34) Rearrangement (FISH) ERG Rearrangement (FISH) TFE3 (Xp11,2) Rearrangement (FISH) for Renal Cell CA & Other Tumors TFEB (6p21) Rearrangement (FISH) for Renal Cell Carcinoma UroVysion™ (FISH) (Bladder Cancer)

GLIOMA

BRAF (7q34) Rearrangement (FISH) IDH1 and IDH2 Mutations (Sanger) 1p/19q Deletion (FISH) BRAF V600E/V600K Mutations (PCR) MGMT Promoter Methylation (PCR) TERT Promoter Mutation (PCR)

LUNG CANCER

Lung Cancer (NGS) Panel* EGFR Mutation (NGS) BRAF V600E/V600K Mutations (PCR) KRAS Mutation (NGS) ALK Rearrangement for NSCLC (FISH) ROS1(6q22) Rearrangement (FISH) RET (10q11) Rearrangement (FISH) PD-L1 (IHC) MET Amplification (FISH)

MELANOMA

Melanoma (NGS) Panel*

BRAF (7q34) Rearrangement (FISH) BRAF V600E/V600K Mutations (PCR) KIT Mutation for Melanoma -Exons 11,13,17 (Sanger) NRAS Mutation (NGS) Chromosomal (Microarray) for Melanoma Multiprobe (FISH) for Melanoma TERT Promoter Mutation (PCR)

PROSTATE CANCER

Prostate Cancer Antigen 3 (PCA3) MyProstateScore (MPS)

SARCOMA

SYT/SSX Translocation (PCR) PAX/FOXO1 Translocation (PCR) EWSR1/WT1 Translocation (PCR) EWSR1/ATF1 Translocation (PCR) EWSR1/FLI1 & EWSR1/ERG Translocation (PCR) EWSR1 (22q12) Rearrangement (FISH) MDMD2 Amplification (FISH) CIC (19q13) Rearrangement (FISH)

THYROID CANCER

BRAF V600 E/V600K Mutations (PCR) BRAF (7q34) Rearrangement (FISH) TERT Promoter Mutation (PCR)

MISCELLANEOUS

Solid Tumor (NGS) Panel*

Biliary Tract Malignancy (FISH) Bone Marrow Transplant Engraftment Analysis (PCR) Circulating Tumor Cells for Breast, Colorectal and Prostate Cancer HER2 (FISH) UGT1A1 Promoter Genotyping (PCR)

SELECT TEST MENU CONTINUED

Genetics (Germline)

AUTISM SPECTRUM DISORDERS/ INTELLECTUAL DISABILITY

Chromosomal Microarray Analysis Fragile X Syndrome Mutation Prader-Willi /Angelman Syndrome CDKL5 Gene Sequencing GDI1 Gene Sequencing MBD5 Gene Sequencing MEF2C Gene Sequencing NLGN3 Gene Sequencing SHANK2 Gene Sequencing SHANK3 Gene Sequencing SLC9A6 Gene Sequencing UBE3A Gene Sequencing

MECP2 (RETT SYNDROME)

MECP2 Gene Sequencing MECP2 Deletion/Duplication MECP2 Targeted Sequencing Familial

PTEN HARMARTOMA TUMOR SYNDROME

PTEN Gene Sequencing PTEN Deletion/Duplication PTEN Targeted Sequencing Familial

BREAST AND OVARIAN CANCER

BRCA1 and BRCA2 Gene Sequencing BRCA1 and BRCA2 Targeted Sequencing, Familial BRCA1 and BRCA2 Deletion/Duplication BRCA Ashkenazi Jewish Founder Mutations BRCA Mutation Panel Hereditary Breast and Ovarian Cancer (HBOC) Comprehensive Germline NGS Panel Hereditary Breast and Ovarian Cancer (HBOC) High-Moderate Risk Germline NGS Panel PTEN Gene Sequencing PTEN Deletion/Duplication TP53 Gene Sequencing TP53 Deletion/Duplication

COLORECTAL CANCER

Colorectal Cancer Germline NGS Panel MSH2 Gene Sequencing

CYSTIC FIBROSIS

Cystic Fibrosis Carrier Screening Cystic Fibrosis Full Gene Sequencing Cystic Fibrosis Deletion/Duplication Cystic Fibrosis Diagnostic Mutation Detection Cystic Fibrosis Targeted Sequencing Familial

HEARING LOSS

GJB2 (Connexin 26) Mutation Analysis GJB2 (Connexin 26) Targeted Sequencing Familial GJB6 (Connexin 30) Deletion Analysis WFS1 (Wolfram Syndrome) Gene Sequencing

NOONAN SYNDROME

PTPN11 Gene Sequencing KRAS Gene Sequencing RAF1 Gene Sequencing SOS1 Gene Sequencing

FRAGILE X SYNDROME Fragile X Syndrome Mutation Detection

LI-FRAUMENI SYNDROME

TP53 Gene Sequencing TP53 Deletion/Duplication

NEUROFIBROMATOSIS NF1 Gene Sequencing

SPINAL MUSCULAR ATROPHY SNM1 and SNM2 Deletion/Duplication

MISCELLANEOUS

Apolipoprotein E Genotyping Factor V Leiden Mutation Hereditary Hemochromatosis Mutation Prothrombin 20210 Mutation

CANCER GERMLINE NGS PANELS (64 GENES)

Colorectal Cancer Germline NGS Panel

19 Genes: MLH1, MSH2, MSH6, MUTYH, PMS2, EPCAM, APC, TP53, PTEN, STK11, SMAD4, BMPR1A, CDH1, CHEK2, GREM1, POLD1, POLE, ATM, AXIN2

Endometrial/Uterine Cancer Germline NGS Panel

13 Genes: BRCA1, BRAC2, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, TP53, STK11, POLD1

Hereditary Breast and Ovarian Cancer Comprehensive Germline NGS Panel 21 Genes: ATM, BARD1, BRAC1, BRAC2, BRIP1, CDH1, STK11, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, FANCC, XRCC2

Hereditary Breast and Ovarian Cancer High-Moderate Risk Germline NGS Panel 9 Genes: ATM, BRAC1, BRAC2, BRIP1, CDH1, CHEK2, PALB2, PTEN, TP53

Melanoma Cancer Germline NGS Panel 6 Genes: BRCA1, BRCA2, CDKN2A, CDK4, TP53, PTEN

Neurofibromatosis Germline NGS Panel 3 Genes: NF1, NF2, SPRED1

Pancreatic Cancer Germline NGS Panel 18 Genes: APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, CDK4, BMPR1A, SMAD4, VHL, XRCC2

Paraganglioma Cancer Germline NGS Panel

12 Genes: SDHAF2, MAX, TMEM127, FH, MEN1, NF1, RET, VHL, SDHB, SDHC, SDHD, SDHA

Prostate Cancer Germline NGS Panel 6 Genes: BRCA1, BRCA2, CHEK2, HOXB13, NBN, TP53

Renal Cancer Germline NGS Panel 19 Genes: VHL, PMS2, PTEN, TP53, EPCAM, FH, FLCN, MET, MLH1, MSH2, MSH6, SDHB, SDHC, SDHD, SDHA, BAP1, TSC1, TSC2, MITF

Stomach Cancer Germline NGS Panel 11 Genes: MLH1, MSH2, MSH6, EPCAM, PMS2, APC, TP53, STK11, CDH1, BMPR1A, SMAD4

> Expertise Delivered Professionally

> > V.02052020